INTRODUCTION AND OBJECTIVES:
While the use of neoadjuvant TIP (paclitaxel, ifosfamide, and cisplatinin) has been well described, the use of adjuvant chemotherapy (ACT) in the treatment of node positive squamous cell carcinoma (SCC) of the penis is controversial and there has been few large studies looking at utilization and outcomes. We sought to describe the use of adjuvant chemotherapy in patients with lymph node positive disease (Nþ) penile cancer using a large nationwide U.S. cancer database.
METHODS: The National Cancer Data Base (NCDB) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) was used to extract all patient with non-metastatic SCC of the penis who underwent partial or total/radical penectomy with inguinal lymph node dissection. Only patients found to have Nþ were included in our cohort. Patients were categorized according to receipt of ACT. Descriptive statistics were used to compare patients according to receipt of ACT. Multivariable logistic regressions were performed to determine patient, tumor or facility characteristics associated with use of ACT. Finally, multivariable Cox regression analysis was used to determine the impact of ACT on overall survival (OS).
RESULTS: A total of 661 patients with NþM0 penile SCC were identified. Of these, 253 (38.3%) patients underwent ACT. Median age at diagnosis was 59 in those who received ACT and 65 in those who did not (p<0.001). After adjusting for all variables, ACT was more likely to be administered to patients with a lower Charlson-Deyo Score CONCLUSIONS: More the a third of patients with Nþ SCC of the penis receive ACT. Other than more advanced disease, many patient and facility characteristics are associated with receipt of ACT. We did not find significant differences in overall survival according to receipt of ACT. Further studies are needed to better define the role of ACT in advanced SCC of the penis. METHODS: Using an international, multicenter, retrospective cohort of PSCC patients, we identified 743 patients who underwent regional lymph node dissection (LND) between 1980 and 2017. Outcomes were examined using Kaplan-Meier, adjusted logistic and Cox regression models. RESULTS: Of the 689 patients suitable for analyses, 328 (47.6%) were cN0. There were 141 (43%) cN0pN0 and 187 (57%) cN0pNþ patients. cN0pNþ patients had more vascular invasion (P[0.001) and more HPV-negative tumors (P<0.001) compared to cN0pN0 patients. On adjusted logistic regression analysis, advanced age (P[0.03), bilateral LND (P[0.02) and time from PT surgery to LND surgery !3 months (OR [2.11; P[0.02) were independent predictors of pNþ disease in cN0 patients. On multivariable Cox regression analysis, node density (OR[6.82; 95% CI 2.32-12.1, P<0.001) and pN2-3 stage (overall P<0.01) were significantly associated with overall survival in cN0 patients.
CONCLUSIONS: Using the largest available retrospective cohort of PSCC patients undergoing regional LND, we identified several histopathological and patient-related prognosticators of pNþ disease and survival in cN0 patients. These factors can be used to enhance patient prognostication and clinical decision-making.
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MP49-11 RESULTS OF A 10 YEAR MULTICENTRE EXPERIENCE OF ADJUVANT RADIOTHERAPY FOR PN3 SQUAMOUS CELL CARCINOMA OF THE PENIS (SCCP)
INTRODUCTION AND OBJECTIVES: Evidence for adjuvant radiotherapy in the management of node positive squamous cell carcinoma of the penis (SCCp) is scant owing to the rarity of the disease. Our supra-network policy has been to recommend adjuvant radiotherapy with concomitant low dose cisplatin delivered with radical intent for any patients with pN3 (TNM 7) SCCp of the groin or pelvis
